Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables - Other: 2016-2018

Historic Receivables - Other for Adma Biologics (ADMA) over the last 3 years, with Dec 2018 value amounting to $961,145.

  • Adma Biologics' Receivables - Other fell 22.84% to $961,145 in Q4 2018 from the same period last year, while for Dec 2018 it was $961,145, marking a year-over-year decrease of 22.84%. This contributed to the annual value of $961,145 for FY2018, which is 22.84% down from last year.
  • According to the latest figures from FY2018, Adma Biologics' Receivables - Other is $961,145, which was down 22.84% from $1.2 million recorded in FY2017.
  • Over the past 5 years, Adma Biologics' Receivables - Other peaked at $1.2 million during FY2017, and registered a low of $961,145 during FY2018.
  • In the last 3 years, Adma Biologics' Receivables - Other had a median value of $969,675 in 2016 and averaged $1.1 million.
  • In the last 5 years, Adma Biologics' Receivables - Other rose by 28.46% in 2017 and then fell by 22.84% in 2018.
  • Adma Biologics' Receivables - Other (Yearly) stood at $969,675 in 2016, then rose by 28.46% to $1.2 million in 2017, then dropped by 22.84% to $961,145 in 2018.